首页> 外文期刊>Journal of drug targeting >Relationship between tumor cell load and sensitivity to the cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2.
【24h】

Relationship between tumor cell load and sensitivity to the cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2.

机译:肿瘤细胞负荷与两种新型铂-胆汁酸复合物Bamet-D3和Bamet-UD2对细胞抑制作用的敏感性之间的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Based on the organotropic characteristics of bile acids towards the liver and the intestine, two novel compounds of the Bamet family, containing at least one bile acid moiety bound to platinum(II), have been synthesized and their cytostatic effect compared to their ability to become accumulated in tumor cells of hepato-intestinal origin. Bamet-UD2 [cis-diammine-bis-ursodeoxycholic platinum(II)] induced a marked inhibition of cell growth, which was more marked in human hepatoblastoma HepG2 and mouse hepatoma Hepa 1-6 cells than in rat hepatoma McA-RH7777 and human colon adenocarcinoma LS 174T cells. This effect was similar to that observed for cisplatin and stronger than that previously reported for other members of this family, such as Bamet-H2 and Bamet-R2. By contrast, Bamet-D3 [(N'N'' cis-dichloro N(3-3-amminepropylammine)propyl) glycocholamide platinum (II)] was only effective in reducing growth in human hepatoblastoma HepG2 cells. Because the in vitro DNA-reactivity was approximately 5-fold higher for Bamet-D3 than for Bamet-UD2, an additional cause for the difference in their cytostatic abilities was sought, investigating the relationship between cell load and the cytostatic effect of the drugs. Drug uptake by two cell lines, Hepa 1-6 and HepG2, with different sensitivities to these compounds was measured. The cellular uptake of Bamet-D3 and Bamet-UD2 was several-fold higher than that of cisplatin. No significant difference in the amount of both drugs taken up by these cell types was found. A study on sodium-dependency and substrate specificity indicated that Hepa 1-6 cells take up Bamet-D3 and Bamet-UD2 via similar mechanism(s), whereas these compounds do not seem to share the uptake pathways in HepG2 cells. Measurement of cell viability by formazan formation from tetrazolium salts and by neutral red uptake, after short-term (6 h) exposure to the desired drug, indicated that no acute toxic effect occurs in the presence of cisplatin or Bamet-D3 in either HepG2 or Hepa 1-6 cells. By contrast, in both cell lines Bamet-UD2 induced acute cell toxicity in a dose-dependent fashion. In sum, the results indicate that tumor cells efficiently take up these two novel compounds of the Bamet family. Although the exact uptake mechanism remains unknown, it seems to be dependent on the cell type. However, the cell load does not account for the differences in the anti-proliferative properties of the drugs. The strong and promising cytostatic activity of Bamet-UD2 is additionally related to its ability, absent in Bamet-D3, to acutely alter cellular functions other than proliferation.
机译:基于胆汁酸对肝脏和肠道的趋向性特征,已合成了Bamet家族的两种新型化合物,其中至少含有一个与铂(II)结合的胆汁酸部分,并且与它们成为细胞的能力相比,它们具有抑制细胞生长的作用。积累在肝肠源性肿瘤细胞中。 Bamet-UD2 [顺式-二氨基-双-熊去氧胆酸铂(II)]诱导了明显的细胞生长抑制作用,在人肝母细胞瘤HepG2和小鼠肝癌Hepa 1-6细胞中比在大鼠肝癌McA-RH7777和人结肠中更明显腺癌LS 174T细胞。该作用与顺铂相似,并且比先前报道的该家族其他成员(如Bamet-H2和Bamet-R2)更强。相比之下,Bamet-D3 [(N'N''顺式二氯N(3-3-氨基丙基丙基氨基)丙基)糖胆酰胺铂(II)仅有效减少人肝母细胞瘤HepG2细胞的生长。由于Bamet-D3的体外DNA反应性大约是Bamet-UD2的5倍,因此寻找其细胞抑制能力差异的另一个原因,以研究细胞载量与药物的细胞抑制作用之间的关系。测量了两个细胞系Hepa 1-6和HepG2对这些化合物的敏感性不同的药物吸收情况。 Bamet-D3和Bamet-UD2的细胞摄取量比顺铂高几倍。在这些细胞类型中吸收的两种药物的量均未发现显着差异。对钠依赖性和底物特异性的研究表明,Hepa 1-6细胞通过相似的机制吸收Bamet-D3和Bamet-UD2,而这些化合物似乎在HepG2细胞中没有共享摄取途径。短期(6 h)暴露于所需药物后,通过四唑鎓盐形成甲an和中性红摄取来测量细胞活力,结果表明在HepG2或HepG2中,在存在顺铂或Bamet-D3的情况下没有发生急性毒性作用。肝1-6个细胞。相反,在两种细胞系中,Bamet-UD2均以剂量依赖性方式诱导急性细胞毒性。总之,结果表明肿瘤细胞有效地吸收了Bamet家族的这两种新化合物。尽管确切的摄取机制仍然未知,但它似乎取决于细胞类型。但是,细胞负荷不能解释药物抗增殖特性的差异。 Bamet-UD2强大而有希望的细胞抑制活性还与其在Bamet-D3中不具备的改变细胞功能(而非增殖)的能力有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号